NCT05768464View on ClinicalTrials.gov

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Non-clear Renal Cell Carcinoma
Interventions
DRUG

Toripalimab

240mg intravenously every 3 weeks

DRUG

Axitinib

5mg orraly twice daily

Trial Locations (2)

210000

RECRUITING

Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing

Unknown

RECRUITING

Hongqian Guo, Nanning

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER